Semaglutide targets MASH molecular pathways beyond weight loss
Nature Medicine, Published online: 01 September 2025; doi:10.1038/s41591-025-03927-w A proteomic study begins to identify the direct and indirect effects of GLP-1 treatment on metabolic dysfunction-associated steatohepatitis (MASH), and reveals insights into treatment-induced changes in liver histology.
Surgeon weighs in on bariatric surgery vs weight loss drugs to beat obesity: Do GLP-1 drugs work better?
Bariatric surgery and GLP-1 medications are significant treatment methods for obesity, but require ongoing lifestyle management and have likely side effects.
Monthly News Roundup – August 2025
Wegovy Granted Accelerated Approval as First GLP-1 Treatment for the Treatment of MASH Novo Nordisk’s Wegovy (semaglutide) has received US Food and Drug Administration (FDA) accelerated approval for the treatment of noncirrhotic metabolic…
You Can’t Walk Your Way Out of Disability
I love a good publishing scandal. They’re usually highbrow enough that you don’t feel cheap for being engaged by them, stupid enough to give you excellent schadenfreude, and low-stakes enough that you don’t walk away wishing you and everyone involved was dead. This summer’s excellent offering in the form probably came out of the blue […]
Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents
Alcohol use disorder (AUD) remains a major public health problem, with few effective medications currently available. However, peptides of the gut-brain axis appear to offer promising therapeutic targets for AUD as they influence the mesolimbic reward circuitry. Here, we examined the effects of tirzepatide, a long-acting dual glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide […]
GLP-1 agonists, a class of weight loss drugs, can halve heart patients’ risk of early death, study finds
submitted by /u/Cresomycin [link] [comments]
Weight loss drugs can halve heart patients’ risk of early death, study finds
GLP-1 agonists could be given to millions with heart conditions to help them stay out of hospital and live longer Weight loss drugs can reduce by half the risk of heart patients being hospitalised or dying early, according to the largest study of its kind. The class of drugs, known as GLP-1 agonists, have been […]
How Your Microbiome Influences Your Dietary Recommendations
Editor’s Note: This article is a reprint. It was originally published April 21, 2024. In the ever-evolving field of bioenergetic medicine, the relationship between our diet, microbiome, and overall health continues to unveil complex and intriguing connections. At the heart of this exploration is the legacy of Ray Peat, Ph.D., whose theories on sugar intake […]
Saturday links: when design fades away
Autos Car buyers are increasingly choosing seven-year car loans. (fa-mag.com) Mainline automakers are struggling to ship software. (ft.com) Why auto production lines can’t be fully automated. (wsj.com) EVs EV charging networks have expanded more than you think. (wsj.com) National parks are still kind of a no-go zone for EV chargers. (bloomberg.com) Cadillac has been on […]
Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP
Abstract BACKGROUND KALVAP is an angiotensin-converting enzyme inhibitor derived from Ziziphus jujuba, but shows poor dipeptidyl peptidase (DPP)-IV inhibitory activity. To remedy this shortcoming, KALVAP was modified according to the distinctive features of DPP-IV inhibitory peptides, yielding nine novel peptides. The DPP-IV inhibitory activity of the peptides was further verified in vitro and in vivo. […]